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Case Report
A 57-year-old man with history of hypertension, hyperlipidemia,
and gout presented for evaluation of both a perioral infection
and an infection in his right great toe from an injury on the
beach at his shore house. The toe trauma was complicated by
a massive hematoma and phlebitis, which required antibiotics.
His primary care physician ordered basic laboratory studies that
showed an anemia and thrombocytopenia. He was sent to a
Hematology and Oncology specialist and subsequently directly
admitted to Thomas Jefferson University Hospital for blood
transfusion and further work-up. Upon further questioning, the
patient admitted to chills starting 2 weeks prior to admission,
elevated temperatures, rigors, dizziness, weakness, shortness of
breath and a weight loss of about 16 pounds over 1 month. He
denied prolonged bleeding or easy bruising, but did admit to
recurrent upper respiratory infections.
On admission, the patient’s white blood cell count was 8.9 x103 /
µL, hemoglobin was 4.1 g/dL, and platelets were 5,000 /µL. There
was a lymphocytic predominance on the manual differential.
On physical exam, the patient was in no acute distress. He was
awake, alert and oriented to person, place, and time. Vitals
signs at that time showed the patient to be afebrile at 99.5 F and
tachycardic at 112 beats per minute, with a respiratory rate of
16 breaths per minute, a blood pressure of 155/90 mm Hg, and
an oxygen saturation 100% on room air. The patient’s heart
and lung exams were both unremarkable. The only significant
finding on exam was edema and tenderness over the entire right
great toe.
Following admission, the patient underwent a bone marrow
biopsy that revealed acute myeloid leukemia (AML) with
markedly decreased background maturing trilineage
hematopoiesis. Upon discussion with the patient, his family, and
the medical team, it was determined that the patient would be
initiated on induction chemotherapy with 7 days of cytarabine
and 3 days of daunorubicin (7+3). Initiation of the induction
therapy however, was delayed due to the infection in his right
1st toe. Radiography and magnetic resonance imaging of the
right 1st toe revealed extensive osteomyelitis involving the right
first proximal and distal phalanges; cultures of the toe fluid
eventually grew Pseudemonas aeruginosa. Vascular surgery was
promptly consulted and the patient underwent amputation of the
right 1st toe. Chemotherapy was initiated a week after amputation
to allow for a period of treatment of the Pseudomonas and wound
healing prior to inducing further immunosuppression.
Before and during chemotherapy, the patient had intermittent
fevers with a peak at 102 F. Blood and urine cultures were
obtained with the fevers, but the cultures were sterile. It was
deemed likely that the fevers were due to tumor burden, but
cultures were continually sent with each elevated temperature

as a precaution. The patient tolerated his 7+3 chemotherapy and
required several packed red blood cell and platelet transfusions
during his stay. He had been doing quite well after chemotherapy
and was almost 1 month post-treatment when he developed
severe rigors and had temperatures up to 103 F during a platelet
transfusion. Blood cultures were again sent, though all blood
cultures prior to that day had been negative. It was initially
thought that antibodies to foreign material in the platelet
transfusion that the patient was receiving caused the rigors.
During his second episode of rigors, the patient had episodes
of desaturations to as low as 80% while on 6 L nasal cannula.
His saturations improved with bronchodilators and increased
oxygen therapy via a non-rebreather facemask. A computed
tomographic scan of the chest revealed pulmonary infiltrates
in bilateral lower lung segments with developing pleural
effusions and mild pulmonary edema. The patient continued
to have rigors and elevated temperatures despite initiation
of broad-spectrum antibiotics and desaturated to an oxygen
saturation percentage in the high 80s and low 90s. He was
quickly transferred to the medical respiratory intensive care
unit for further care and management. On the next day, blood
cultures grew Acinetobacter baumannii that was pan-resistant
to the patient’s current broad-spectrum antibiotic regimen of
aztreonam, ciprofloxacin, tobramycin, and vancomycin. He was
intubated for respiratory distress and started on vasopressors. His
clinical picture continued to deteriorate, and on the morning of
hospital day 30 he expired.

Discussion
Acute Myeloid Leukemia and Neutropenic Fever
AML is a hematologic cancer characterized by an elevated number
of myeloid cells in the bone marrow. This disease often causes
arrested maturation of hematopoietic cells, leading to anemia,
thrombocytopenia, leukopenia with neutropenia specifically,
and sometimes a leukocytosis with poorly functioning or
diminished granulocytes. 1 Patients initially present with
symptoms of fatigue due to anemia, bleeding from thrombocytopenia, and infection or fever due to inadequately functioning
white blood cells. 1,2 Patients may also present with pallor,
shortness of breath, or as in this patient’s presentation, with
non-healing wounds. Additionally, leukemic cell abnormalities
may affect a variety of other tissues and organs, causing various
other organ-specific symptoms.1,2
Diagnosis of AML is routinely done via bone marrow biopsy
and examination of the aspirate under microscopy. Detection
of at least 30% myeloblasts with round or irregular nuclei,
little cytoplasm and the presence of cytoplasmic Auer rods
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(azurophilic granules within lysosomes) confirms the diagnosis
of AML.1,2
The primary objective in treating AML is inducing remission and
preventing recurrence of disease. Remission in AML is defined
by finding less than 5% of myeloblast cells in the bone marrow
aspirate and by having the recovery of hemoglobin, platelet, and
white blood cells levels to normal ranges in peripheral blood. The
standard of treatment for AML is daunorubicin and cytarabine.
Daunorubicin is typically given for 3 days, while cytarabine is
given for 7 days, thus giving the commonly used name of “7+3
induction therapy.”1,2 Remission rates for patients under the age
of 60 on this combination therapy is as high as 80%, but as with
all chemotherapy agents, neutropenia is a common and severe
side effect which may lead to morbidity and mortality from
infections.1,2
The effects of prolonged neutropenia have been well described
for nearly 40 years. The risk of infection substantially increases
when the absolute neutrophil count (ANC) is less than 500 cells/
mm3. Many acquired infections in the neutropenic host are
related to skin and mucosal breakdown that commonly manifests
as mucositis or typhlitis. Translocation from the gastrointestinal tract with gram-negative and anaerobic pathogens is
a common cause of febrile illness in neutropenic patients. It is
has been hypothesized that mucositis that often accompanies
chemotherapy can provide an entry to the blood stream for
enteric pathogens. Other predisposing factors for developing
infections include rapidly declining ANC, increasing duration of
neutropenia, unresponsiveness of cancer to chemotherapy, and
use of peripheral or central venous catheters.3
Gram-negative bacilli, particularly Pseudomonas aeruginosa,
are the pathogens of particular concern. Monotherapy with
beta-lactams, carbapenems, and 3rd generation cephalosporins are common initial therapies for patients with febrile
neutropenia.3,4 Typically, gram-positive antimicrobial therapy
is not empirically started at initial presentation, unless the patient
has obvious mucosal barrier breakdown. Vancomycin and
linezolid are common gram-positive antimicrobials prescribed
in this setting. It is recommended however, that cessation of
gram-positive coverage should occur if cultures remain negative
for 72 hours.4 Fungal pathogens are also of concern, particularly
after one to two weeks of neutropenia. Candida albicans is often
implicated in central venous catheter infections, and Aspergillus
species commonly cause invasive pneumonias, sinusitis, and skin
ulcers. As a result, antifungals are typically added after the patient
has had four or more days of neutropenia and fevers.5
Our patient had several risk factors for developing life-threatening
infection. He was functionally neutropenic on the day of
admission, and remained profoundly neutropenic for his entire
hospitalization, as his neutrophil percentage remained below
10% of the leukocyte differential. Additionally, he also had a
peripherally inserted central catheter in his right upper extremity,
although this never appeared indurated or erythematous. Our
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patient was also on all the appropriate antimicrobial therapies
given the duration and severity of his neutropenia. On the
day the patient developed rigors and positive blood cultures,
he received aztreonam, caspofungin, ciprofloxacin, acyclovir,
metronidazole, tobramycin, vancomycin, and voriconazole.
Despite these broad-spectrum, potent combinations of antimicrobials, he still had fevers and eventually the positive blood
cultures speciated out a strain of Acinetobacter baumanii that
was highly resistant to all of the patient’s current antibiotics.

Acintobacter Baumannii:
Acinetobacter species are aerobic, gram-negative bacilli commonly
found in aquatic environments and in soil, and have become
an increasingly important pathogen in nosocomial infections.
Unfortunately, strains of acinetobacter are becoming increasingly
resistant to common antimicrobials leading to a higher incidence
in mortality. A 2005 study from Korea aimed to identify mortality
risk factors in patients with Acinetobacter baumannii bacteremia.
Their results identified an association with neutropenia as well as
with an elevated Acute Physiology and Chronic Health Evaluation
II (APACHE II) score. The authors point to a mortality rate
between 17-52%.6 Additional studies have shown resistance
patterns in Acinetobacter baumannii infections. In a 3-month
study by Landman, et al. from Brooklyn, NY, it was found that
53% of the 419 strains isolated in 15 hospitals were resistant to
meropenem and/or imipenem and of these, 12% were resistant
to all standard antibiotics.7
Given the multi-drug resistant patterns of Acinetobacter
baumannii, it has been proposed that colistin may be one of the
few antibiotics capable of combating these infections. Colistin,
a polymyxin antibacterial, was first available for use in 1959.
It is a bactericidal medication that binds to lipopolysaccharides
and phospholipids in the outer cell membrane of gram-negative
bacteria. This causes a disruption in the membrane leading to
bacterial lysis and spillage of intracellular contents.8 Colistin fell
out of favor in the 1980’s largely due to concerns of nephrotoxicity, neurotoxicity, and neuromuscular blockade. It has
had a comeback of sorts recently due to demonstrated in-vitro
bactericidal activity against gram-negative bacilli and relatively
low resistance patterns. A small study from Brazil showed
treatment with colistin resulted in a “good outcome,” defined
by negative blood cultures, cessation of fever, and prevention
of mortality for 35 out of 59 cases of Acinetobacter infections.
This study does, however, report that 22 of the 59 patients
died, although of unreported causes. One could argue that a
“good outcome” is not an objective measurement and that no
parameters were discussed regarding said outcome. Additionally,
further quantification of so-called “good outcomes” should be
clarified, especially when 22 of the patients in this small study
died. Additionally, the authors describe an increase in the
baseline serum creatinine in 32% of patients in the study due
to colistin.8

The Medicine Forum

Conclusion
The complications of AML and neutropenia are a daily
challenge to physicians caring for patients with this disease.
The diseases itself, as well as all treatments for the disease
predispose these patients to unique pathogens that can cause
catastrophic harm or death. In an era of multi-drug resistant
pathogens, clinicians must remain hyper vigilant for newly
emerging resistance patterns and know how to combat these
lethal microbes with appropriate antibiotics. If drug resistant
bacteria are considered, swift action must be undertaken with
aggressive antibiotics and potential infectious disease specialist
consultation. Acinetobacter infections, although less common,
have proven to be notoriously difficult to treat and potentially
deadly.
Our patient in the intensive care unit did undergo a change in
antibiotic coverage from aztreonam to meropenem, but he did
not receive colistin. It is unlikely that using colistin would have
helped given his clinical picture of profound gram-negative
septic shock. Had our patient received colistin in the first hours
of his rigors his outcome may have been different. Although
it is impossible to predict, the astute clinician must always be
aware of the multitude of resistant organisms and the arsenal
of potential life-saving treatments against them. The challenge

remains to develop new antimicrobials to keep up with the
ever-changing patterns of bacterial disease.
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